Abstract
Introduction
Patient-derived skin fibroblasts offer a unique translational model to study molecular mechanisms of multiple human diseases. Metabolomics profiling allows to track changes in a broad range of metabolites and interconnected metabolic pathways that could inform on molecular mechanisms involved in disease development and progression, and on the efficacy of therapeutic interventions. Therefore, it is important to establish standardized protocols for metabolomics analysis in human skin fibroblasts for rigorous and reliable metabolic assessment.
Objectives
We aimed to develop an optimized protocol for concurrent measure of the concentration of amino acids, acylcarnitines, and components of the tricarboxylic acid (TCA) cycle in human skin fibroblasts using gas (GC) and liquid chromatography (LC) coupled with mass spectrometry (MS).
Methods
The suitability of four different methods of cell harvesting on the recovery of amino acids, acylcarnitines, and TCA cycle metabolites was established using GC/MS and LC/MS analytical platforms. For each method, metabolite stability was determined after 48 h, 2 weeks and 1 month of storage at − 80 °C.
Results
Harvesting cells in 80% methanol solution allowed the best recovery and preservation of metabolites. Storage of samples in 80% methanol up to 1 month at − 80 °C did not significantly impact metabolite concentrations.
Conclusion
We developed a robust workflow for metabolomics analysis in human skin fibroblasts suitable for a high-throughput multiplatform analysis. This method allows a direct side-by-side comparison of metabolic changes in samples collected at different time that could be used for studies in large patient cohorts.
Similar content being viewed by others
Data availability
All data generated or analyzed during this study are included in this publication. All raw data collected in this study was uploaded to the Metabolomics Workbench: NIH Data Repository (website: https://www.metabolomicsworkbench.org/).
References
Cao, B., Aa, J., Wang, G., Wu, X., Liu, L., Li, M., et al. (2011). GC-TOFMS analysis of metabolites in adherent MDCK cells and a novel strategy for identifying intracellular metabolic markers for use as cell amount indicators in data normalization. Analytical and Bioanalytical Chemistry, 400, 2983–2993.
Chace, D. H., Diperna, J. C., Mitchell, B. L., Sgroi, B., Hofman, L. F., & Naylor, E. W. (2001). Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clinical Chemistry, 47, 1166–1182.
Chrysanthopoulos, P. K., Goudar, C. T., & Klapa, M. I. (2010). Metabolomics for high-resolution monitoring of the cellular physiological state in cell culture engineering. Metabolic Engineering, 12, 212–222.
Danielsson, A. P., Moritz, T., Mulder, H., & Spegel, P. (2010). Development and optimization of a metabolomic method for analysis of adherent cell cultures. Analytical Biochemistry, 404, 30–39.
Deberardinis, R. J., & Thompson, C. B. (2012). Cellular metabolism and disease: What do metabolic outliers teach us? Cell, 148, 1132–1144.
Dettmer, K., Nurnberger, N., Kaspar, H., Gruber, M. A., Almstetter, M. F., & Oefner, P. J. (2011). Metabolite extraction from adherently growing mammalian cells for metabolomics studies: Optimization of harvesting and extraction protocols. Analytical and Bioanalytical Chemistry, 399, 1127–1139.
Dutta, T., Kudva, Y. C., Persson, X. M., Schenck, L. A., Ford, G. C., Singh, R. J., et al. (2016). Impact of long-term poor and good glycemic control on metabolomics alterations in type 1 diabetic people. Journal of Clinical Endocrinology and Metabolism, 101, 1023–1033.
Fiehn, O., Kopka, J., Trethewey, R. N., & Willmitzer, L. (2000). Identification of uncommon plant metabolites based on calculation of elemental compositions using gas chromatography and quadrupole mass spectrometry. Analytical Chemistry, 72, 3573–3580.
Guasch-FERRE, M., Hruby, A., Toledo, E., Clish, C. B., Martinez-Gonzalez, M. A., Salas-Salvado, J., et al. (2016). Metabolomics in prediabetes and diabetes: A systematic review and meta-analysis. Diabetes Care, 39, 833–846.
Han, J., Gagnon, S., Eckle, T., & Borchers, C. H. (2013). Metabolomic analysis of key central carbon metabolism carboxylic acids as their 3-nitrophenylhydrazones by UPLC/ESI-MS. Electrophoresis, 34, 2891–2900.
Hernandez Bort, J. A., Shanmukam, V., Pabst, M., Windwarder, M., Neumann, L., Alchalabi, A., et al. (2014). Reduced quenching and extraction time for mammalian cells using filtration and syringe extraction. Journal of Biotechnology, 182–183, 97–103.
Kapoore, R. V., Coyle, R., Staton, C. A., Brown, N. J., & Vaidyanathan, S. (2017). Influence of washing and quenching in profiling the metabolome of adherent mammalian cells: a case study with the metastatic breast cancer cell line MDA-MB-231. Analyst, 142, 2038–2049.
Khan, H., Alhomida, S. A., Habib, S., Ali Khan, A., Ola, M., Siddiqui, N. J., et al. (2014). Blood carnitine as a biomarker for acute myocardial infarction. Biomedical Research, 25, 63–66.
Koek, M. M., Muilwijk, B., van der Werf, M. J., & Hankemeier, T. (2006). Microbial metabolomics with gas chromatography/mass spectrometry. Analytical Chemistry, 78, 1272–1281.
Kruger, N. J. (1994). The Bradford method for protein quantitation. Methods in Molecular Biology, 32, 9–15.
Lanza, I. R., Zhang, S., Ward, L. E., Karakelides, H., Raftery, D., & Nair, K. S. (2010). Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS ONE, 5, e10538.
Lecuyer, L., Victor-Bala, A., Deschasaux, M., Bouchemal, N., Nawfal-Triba, M., Vasson, M. P., et al. (2018). NMR metabolomic signatures reveal predictive plasma metabolites associated with long-term risk of developing breast cancer. International Journal of Epidemiology, 47, 484–494.
Lodeiro, M., Ibanez, C., Cifuentes, A., Simo, C., & Cedazo-Minguez, A. (2014). Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer’s disease. Journal of Alzheimer’s Disease, 41, 223–232.
Luo, X., & Li, L. (2017). Metabolomics of small numbers of cells: Metabolomic profiling of 100, 1000, and 10000 human breast cancer cells. Analytical Chemistry, 89, 11664–11671.
Mamer, O., Gravel, S. P., Choiniere, L., Chenard, V., St-Pierre, J., & Avizonis, D. (2013). The complete targeted profile of the organic acid intermediates of the citric acid cycle using a single stable isotope dilution analysis, sodium borodeuteride reduction and selected ion monitoring GC/MS. Metabolomics, 9, 1019–1030.
Martano, G., Delmotte, N., Kiefer, P., Christen, P., Kentner, D., Bumann, D., et al. (2015). Fast sampling method for mammalian cell metabolic analyses using liquid chromatography-mass spectrometry. Nature Protocols, 10, 1–11.
Muschet, C., Moller, G., Prehn, C., de Angelis, M. H., Adamski, J., & Tokarz, J. (2016). Removing the bottlenecks of cell culture metabolomics: Fast normalization procedure, correlation of metabolites to cell number, and impact of the cell harvesting method. Metabolomics, 12, 151.
Nunnari, J., & Suomalainen, A. (2012). Mitochondria: in sickness and in health. Cell, 148, 1145–1159.
Perez, M. J., Ponce, D. P., Osorio-Fuentealba, C., Behrens, M. I., & Quintanilla, R. A. (2017). Mitochondrial bioenergetics is altered in fibroblasts from patients with sporadic alzheimer’s disease. Frontiers in Neuroscience, 11, 553.
Puchalska, P., Martin, S. E., Huang, X., Lengfeld, J. E., Daniel, B., Graham, M. J., et al. (2019). Hepatocyte-macrophage acetoacetate shuttle protects against tissue fibrosis. Cell Metabolism, 29(383–398), e7.
Salek, R. M., Steinbeck, C., Viant, M. R., Goodacre, R., & Dunn, W. B. (2013). The role of reporting standards for metabolite annotation and identification in metabolomic studies. Gigascience, 2, 13.
Ser, Z., Liu, X., Tang, N. N., & Locasale, J. W. (2015). Extraction parameters for metabolomics from cultured cells. Analytical Biochemistry, 475, 22–28.
Shibbani, K., Fahed, A. C., Al-Shaar, L., Arabi, M., Nemer, G., Bitar, F., et al. (2014). Primary carnitine deficiency: novel mutations and insights into the cardiac phenotype. Clinical Genetics, 85, 127–137.
Shukla, S. K., Gunda, V., Abrego, J., Haridas, D., Mishra, A., Souchek, J., et al. (2015). MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget, 6, 19118–19131.
Sorrentino, V., Menzies, K. J., & Auwerx, J. (2018). Repairing mitochondrial dysfunction in disease. Annual Review of Pharmacology and Toxicology, 58, 353–389.
Toledo, J. B., Arnold, M., Kastenmuller, G., Chang, R., Baillie, R. A., Han, X., et al. (2017). Metabolic network failures in Alzheimer’s disease-A biochemical road map. Alzheimers Dement, 13, 965–984.
Trushina, E., Dutta, T., Persson, X. M., Mielke, M. M., & Petersen, R. C. (2013). Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer’s disease using metabolomics. PLoS ONE, 8, e63644.
Wilkins, J. M., & Trushina, E. (2017). Application of metabolomics in alzheimer’s disease. Frontiers in Neurology, 8, 719.
Wu, J., Wuolikainen, A., Trupp, M., Jonsson, P., Marklund, S. L., Andersen, P. M., et al. (2016). NMR analysis of the CSF and plasma metabolome of rigorously matched amyotrophic lateral sclerosis, Parkinson’s disease and control subjects. Metabolomics, 12, 101.
Acknowledgements
This study was supported by the National Institutes of Health NIEHS, NIA, NINDS (Grant Numbers R01ES020715, RF1AG 55549, R01NS107265) and Mayo Clinic Metabolomics Core (NIDDK Grant Number U24DK100469); Mayo Clinic Clinomics; and Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology
Author information
Authors and Affiliations
Contributions
JW, XP, DS, IL, and ET contributed to the design of this study, data analysis and interpretation. JW conducted the experiments and performed the majority of the data analysis. DS and XP conducted metabolomics profiling. JW and ET wrote the manuscript. All authors edited the manuscript and approved the final version.
Corresponding author
Ethics declarations
Conflict of interest
All authors declare no conflict of interest.
Ethical approval
All ethical guidelines and procedures established by the Mayo Clinic Institutional Review Board for the use of human skin fibroblasts were followed in this study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wilkins, J., Sakrikar, D., Petterson, XM. et al. A comprehensive protocol for multiplatform metabolomics analysis in patient-derived skin fibroblasts. Metabolomics 15, 83 (2019). https://doi.org/10.1007/s11306-019-1544-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11306-019-1544-z